A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cancer
Interventions: BIOLOGICAL: Nivolumab|DRUG: Anastrozole|DRUG: Palbociclib
Sponsor: Bristol-Myers Squibb